Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir in COPD
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir…
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…
Health Mobile Apps Landscape in H2 2025
Trending in Health Mobile Apps: Current Trends, Rankings and Insights from H2…
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4 in COPD
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4…
Lucid Diligence Brief: GSK licenses Empirico's siRNA in COPD
Lucid Diligence Brief: GSK licenses Empirico's siRNA in COPD Professional…
ATS 2025 Preview: Key Respiratory Highlights To Watch
ATS 2025 at a glance Prepare for ATS 2025 with LucidQuest’s concise preview,…
Respiratory Weekly News - May 16th 2025
Lung & Respiratory Health Breakthroughs: IPF Patient Voices, Asthma Trial…
How our strategic intelligence helped a respiratory brand, understand the future landscape and adapt its clinical development program (CDP).
The Challenge: Staying updated with the ever-changing competitive landscape in…
How we helped a specialty respiratory company understand the "trends" of severe asthma and COPD assets and position itself strategically.
The Challenge: Staying updated with emerging trends in the respiratory market…
How a leading global player in the respiratory space worked towards speedier access to Russia and China
The Challenge: Leading multinational Pharma company wants to dive deep into key…